Christopher R. Luthers

Christopher R. Luthers

Auto-generated profile, based on publicly available information

Christopher R. Luthers

Department of Microbiology, Immunology, and Molecular Genetics, University of California , Los Angeles, Los Angeles, CA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Acta Biomaterialia
Verified
Journal Article
Closed access
DPDivya B. Patel
Divya B. Patel
CLChristopher R. Luthers
Christopher R. Luthers
MLMax J. Lerman
Max J. Lerman
JFJohn P. Fisher
John P. Fisher
SJSteven Jay
Steven Jay

15 October 2019 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
KVKelsey Voss
Kelsey Voss
CLChristopher R. Luthers
Christopher R. Luthers
KPKatherine Pohida
Katherine Pohida
ASAndrew Snow
Andrew Snow
Restimulation-induced cell death (RICD) is an apoptotic pathway triggered in activated effector T cells after T cell receptor (TCR) re-engagement. RICD operates at the peak of the immune response to ensure T cell expansion remains in check to maintain immune homeostasis. Understanding the biochemical regulation of RICD sensitivity may provide strategies for tuning the magnitude of an effector T cell response. Metabolic reprogramming in activated T cells is not only critical for T cell differentiation and effector functions, but also influences apoptosis sensitivity. We previously demonstrated that aerobic glycolysis correlates with optimum RICD sensitivity in human effector CD8 T cells. However, metabolic programming in CD4 T cells has not been investigated in this context. We employed a pharmacological approach to explore the effects of fatty acid and glycolytic metabolism on RICD sensitivity in primary human CD4 T cells. Blockade of fatty acid synthase (FASN) with the compound C75 significantly protected CD4 effector T cells from RICD, suggesting that fatty acid biosynthesis contributes to RICD sensitivity. Interestingly, sphingolipid synthesis and fatty acid oxidation (FAO) were dispensable for RICD. Disruption of glycolysis did not protect CD4 T cells from RICD unless glyceraldehyde-3-phosphate dehydrogenase (GAPDH) enzymatic activity was targeted specifically, highlighting important differences in the metabolic control of RICD in effector CD4 vs. CD8 T cell populations. Moreover, C75 treatment protected effector CD4 T cells derived from naïve, effector memory, and central memory T cell subsets. Decreased RICD in C75-treated CD4 T cells correlated with markedly reduced FAS ligand (FASL) induction and a Th2-skewed phenotype, consistent with RICD-resistant CD4 T cells. These findings highlight FASN as a critical metabolic potentiator of RICD in human effector CD4 T cells.

28 October 2019 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
KVKelsey Voss
Kelsey Voss
CLCamille Lake
Camille Lake
CLChristopher R. Luthers
Christopher R. Luthers
NLNathaniel M. Lott
Nathaniel M. Lott
BDBatsukh Dorjbal
Batsukh Dorjbal
ASAndrew Snow
Andrew Snow

14 February 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MCMandy I Cheng
Mandy I Cheng
LHLee Hong
Lee Hong
CBChristian Bustillos
Christian Bustillos
BCBryan Chen
Bryan Chen
SCScott Chin
Scott Chin
MSMaureen A Su
Maureen A Su
Hypoxia is a hallmark of inflammatory conditions (e.g., inflammatory bowel disease [IBD]), and adaptive responses have consequently evolved to protect against hypoxia-associated tissue injury. Because augmenting hypoxia-induced protective responses is a promising therapeutic approach for IBD, a more complete understanding of these pathways is needed. Recent work has demonstrated that the histone demethylase UTX is oxygen-sensitive, but its role in IBD is unclear. In this study, we show that hypoxia-induced deactivation of UTX downregulates T cell responses in mucosal inflammation. Hypoxia results in decreased T cell proinflammatory cytokine production and increased immunosuppressive regulatory T cells, and these findings are recapitulated by UTX deficiency. Hypoxia leads to T cell accumulation of H3K27me3 histone modifications, suggesting that hypoxia impairs UTX’s histone demethylase activity to dampen T cell colitogenic activity. Finally, T cell–specific UTX deletion ameliorates colonic inflammation in an IBD mouse model, implicating UTX’s oxygen-sensitive demethylase activity in counteracting hypoxic inflammation.